跳至主要内容
临床试验/ACTRN12623000258651
ACTRN12623000258651尚未招募3 期

Evaluation of the sublingual vaccination MV140 in the prevention of recurrent urinary tract infections in the older adult Australian population - a multi-centre, double-blinded, randomised controlled trial

Australasian Medical & Scientific Ltd.0 个研究点目标入组 150 人开始时间: 2023年3月10日最近更新:

试验速览

阶段
3 期
状态
尚未招募
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Blinded (masking used)

入排标准

年龄范围
65 Years 至 o limit(—)
性别
All

入选标准

  • People aged greater than or equal to 65-years of any gender
  • Recurrent UTI (defined as 3 or more UTIs within the last 12 months)
  • Competence to consent to participate in trial and comply with study requirements

排除标准

  • History of bladder tumours
  • Diagnosed bladder fistula disease
  • Currently receiving immunotherapy for another condition
  • Any immunological disease requiring active treatment
  • Known intolerance/allergy to MV140 or ingredients it contains
  • Known bladder stones
  • Long-term urinary catheter dependence (IDC/SPC)
  • Unable to provide informed consent or meet study requirements

研究者

相似试验